Zelboraf Tablet, Film Coated
Product Images NDC 50242-090

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Zelboraf (NDC 50242-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zelboraf 01)

Chemical structure of Vemurafenib, the active ingredient in ZELBORAF 240 mg film-coated tablets. The diagram shows the molecular structure with relevant chemical bonds and atoms, including chlorine, fluorine, nitrogen, oxygen, sulfur, and hydrogen.*

FDA Label Image

Figure 1 (Zelboraf 02)

A survival curve graph comparing ZELBORAF (vemurafenib) to Dacarbazine over time in months. The Y-axis represents survival probability, and the X-axis represents time up to 14 months. The graph shows two lines with corresponding patient numbers at risk for each treatment group below the X-axis.*

FDA Label Image

Principal Display Panel (240 mg Tablet Bottle Carton)

Zelboraf (vemurafenib) tablets, 240 mg, film-coated oral tablets. The label includes a warning not to crush or chew tablets and indicates prescription use only. The package contains 112 tablets and is labeled by Genentech, Inc. in association with Daiichi Sankyo, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.